S&P 500

5.649,68

0,33%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
07/07/2009	09:07	Marketwired	BridgewaterEquity.com Free Fundamental Sector & Market Research on OCR, GGC, NWD, MPW, ALTH and NEXM	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/07/2009	09:00	Business Wire	Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/06/2009	09:40	PR Newswire (US)	InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren Reso	NASDAQ:ALTH
23/06/2009	19:46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/06/2009	13:53	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/06/2009	07:05	Edgar (US Regulatory)	Proxy Statement (definitive) (DEF 14A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/05/2009	09:00	Business Wire	Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/05/2009	09:00	Business Wire	Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
14/05/2009	19:15	Business Wire	Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/05/2009	09:00	Business Wire	Allos Therapeutics to Present at the Eighth Annual JMP Securities Research Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2009	18:01	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2009	17:00	Business Wire	Allos Therapeutics Reports First Quarter 2009 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/04/2009	09:31	Edgar (US Regulatory)	Amended Annual Report (10-K/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/04/2009	17:00	Business Wire	Allos Therapeutics to Report First Quarter 2009 Results on May 5, 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/04/2009	16:00	Business Wire	Allos Therapeutics’ Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/04/2009	09:00	Business Wire	Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/04/2009	17:00	Business Wire	Allos Therapeutics Announces Closing of Common Stock Offering	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/04/2009	17:10	Edgar (US Regulatory)	Prospectus filed pursuant to Rule 424(b)(5) (424B5)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
31/03/2009	10:00	Business Wire	Allos Therapeutics Announces Pricing of Common Stock Offering	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/03/2009	09:00	Business Wire	Allos Therapeutics to Present at the 4th Annual Citi Biotech Day	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
25/03/2009	09:00	Business Wire	Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell L...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/03/2009	18:30	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/03/2009	09:00	Business Wire	Allos Therapeutics Appoints David M. Stout to Its Board of Directors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/03/2009	09:00	Business Wire	Allos Therapeutics’ Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the Eu...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/03/2009	18:00	Business Wire	Allos Therapeutics Reports 2008 Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/02/2009	18:00	Business Wire	Allos Therapeutics to Report 2008 Results on March 3, 2009	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/02/2009	18:24	Edgar (US Regulatory)	Amended Statement of Ownership (SC 13G/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/02/2009	19:49	Edgar (US Regulatory)	Annual Statement of Changes in Beneficial Ownership (5)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/12/2008	19:00	Business Wire	Allos Therapeutics to Present at the RBC Capital Markets 2008 Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/12/2008	14:03	Business Wire	Allos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of Pralatrexate in Patients with Relapsed or ...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)